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Besides histamine, substance P (SP) has been demonstrated to play a crucial role in pruritic skin diseases. Although antihistamines
are frequently used for pruritic skin diseases, little is known concerning the eﬀect on an SP-induced event such as mast cell
degranulation and the upregulation of adhesion molecules or the nitric oxide (NO) synthesis in endothelial cells. Our aim
was to study the eﬀect of bepotastine besilate on SP-induced degranulation of rat basophillic leukemia (RBL-2H3) cells and
expression of adhesion molecules and NO synthesis in human dermal microvascular endothelial cells (HMVECs). Bepotastine
besilate signiﬁcantly inhibited SP-induced degranulation of RBL-2H3 cells and NO synthesis in HMVECs. Bepotastine besilate
signiﬁcantly inhibited expression of adhesion molecules in HMVESs, while it failed to suppress SP-induced upregulation of the
adhesionmoleculesinHMVECs.Therefore,bepotastinebesilateisassumedtoactfavorablyonSP-inducedbasophildegranulation
and NO synthesis in HMVECs.
Copyright © 2009 Shun Kitaba et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Although second generation antihistamines generally have
been considered to inhibit histamine, recently, their mul-
tifunctional aspects, besides the blockade of histamine sig-
naling, have attracted a great deal of attention. Traditionally,
the eﬃcacy of type 1 histamine receptor (H1) antihistamines
for the treatment of allergic diseases has been primarily
attributedtotheircapacitytoreducetheactivityofhistamine
on H1 receptors expressed on endothelial cells, peripheral
nerve endings, ﬁbroblasts, and epidermal keratinocytes [1–
6]. Therefore, both the ﬁrst, and the second generation
antihistamines are capable of improving the erythema,
cutaneous edema, and itch sensation. Meanwhile, it has been
reported that a second generation antihistamine inhibited
murinecontacthypersensitivitymoremarkedlythantheﬁrst
generation antihistamine [7]. Therefore, it is assumed that
the action of the second generation antihistamines is unique
in the contact hypersensitivity reaction and is not merely
derived from its H1 receptor blocking action; however, little
is known about the unique eﬀects of second generation
antihistamines.
SP is known to contribute to the formation of an allergic
dermatitis via mast cell degranulation and vasodilatation.
Endothelial cells are also known to possibly be substance P-
responsive cells, thereby producing nitric oxide (NO) [8, 9],
whichisknownasavasodilatoryfactor,andexpressadhesion
molecules including ICAM-1 and P-selectin (CD62P) [10,
11] by exposure to SP. From these results, it might be sup-
posed that the inhibition of the SP-elicited response will thus
have a favorable eﬀect on allergic diseases. The SP receptor,
neurokinin-1 receptor (NK1R), which is widely distributed
in peripheral tissues (e.g., endothelial cells, keratinocytes,
mast cells, and ﬁbroblasts) [12, 13], has a 7-transmembrane
receptor, as well as the H1 receptor. As NK1R antago-
nists attenuated the histamine-induced behavioral response
in mice, the existence of crosstalking between H1R and
NK1R has been supposed [14]. Although antihistamines
are expected to attenuate the SP-induced events, the ﬁrst
generation antihistamines such as chlorpheniramine failed2 Journal of Allergy
to inhibit the SP-elicited response [15], second generation
antihistamines have not yet been examined.
In this study, the eﬀect of bepotastine besilate, a second
generation antihistamine, against the SP-induced degranula-
tion of RBL-2H3 and the production of nitrite from human
microvascular endothelial cells was investigated.
2.MaterialsandMethods
2.1.CellCulture. RBL-2H3,abasophilcellline,wasobtained
from the Health Science Research Resources Bank (Osaka,
Japan). The cells were grown in modiﬁed Eagle’s medium
(Gibco-BRL, Gaithersburg, MD, USA) containing 10% fetal
bovine serum (BioWhittaker Inc., Walkersville, MD, USA)
and streptomycin at 37◦Ci na5 %C O 2 atmosphere. Human
microvascular endothelial cells (HMVECs) were obtained
from Clonetics Endothelial Cell Systems (Cambrex Bio
Science. Walkersville Inc., MD, USA) and were cultured in
EBM2medium(SANKOJunyaku,Ibaragi,Japan)containing
20% fetal bovine serum.
2.2. β-Hexosaminidase Release Assay. Degranulation was
determined by measuring the release of β-hexosaminidase.
RBL-2H3 cells were grown on 96 well plates (2 ×
105 cells/well) and preincubated with 100μM pyliramine
(Sigma) or 100ng/mL bepotastine besilate (Mitsubishi Tan-
abe Pharma. Osaka, Japan) for 30 minutes and subsequently
stimulated for 24 hours with 1 × 10
−4 or 1 × 10
−6 Mo f
SP (Sigma). Following stimulation, the supernatant was
incubated with an equal volume of substrate solution (1mM
P-nitrophenyl N-acetyl-beta-d-glucosamine in 0.05M cit-
rate buﬀe r ,p H4 . 5 )f o r1h o u ra t3 7 ◦C. The enzyme
reaction was stopped by the addition of 0.05M sodium
bicarbonate buﬀer (pH 10.0), and the reaction product
was measured at 450nm using a Model 680 Microplate
Reader (BIO-RAD). To determine the total amount of β-
hexosaminidase released, an equal number of cells were lysed
by assay buﬀer containing 1% (v/v) Triton X-100 prior
to incubation with substrate using the same procedure as
for the determination of the activity in the supernatant.
The data were presented as the ratio (%) of the released
β-hexosaminidase/β-hexosaminidase contained in the lysed
cell.
2.3. Enzyme-Linked Immunosorbent Assay (ELISA). The
concentrations of soluble ICAM1 (sICAM1) and soluble
VCAM1 (sVCAM1) in the culture medium derived from
the 24-hour SP-treated HMVECs were measured by using
an R&D ELISA kit. Each kit was used following its recom-
mended protocol to measure each value with a Model 680
Microplate Reader (BIO-RAD).
2.4. Immunochemical Staining of Adhesion Molecules. The
HMVECs were seeded in Lab-Tek chamber slides (NAL-
GENE Labware, Rochester, NY, USA). After 1 day in culture,
the cells were preincubated with 100μM pyliramine or
100ng/mL bepotastine besilate for 30 minute and subse-
quently stimulated for 24 hours with 1 × 10
−4 or 1 ×
10
−6 MS P .T h ec u l t u r ec e l l sw e r er i n s e dw i t hp h o s p h a t e
buﬀered saline (PBS) twice and subsequently ﬁxed with 4%
paraformaldehyde for 15 minutes. After adequate rinsing
with PBS, cells were incubated with murine antihuman
CD62P antibody (Chemicon), rabbit antihuman ICAM-1
(Cell Signaling), and Hoechst33342 (molecular probes) for
20 minutes at room temperature. Antimouse IgG FITC-
conjugated antibody and antirabbit IgG TRITC-conjugated
antibody(DAKO)wereusedassecondaryantibodies.Images
of the immunolabeled sections were captured with an
immunoﬂuorescence microscope BZ-8000 (Keyence, Osaka,
Japan).
2.5. Flow Cytometry. The HMVECs were seeded in 6-well
collagen-coated dishes. After 1 day in culture, the cells
were preincubated with 100μM pyliramine or 100ng/mL
bepotastine besilate for 30 minutes and subsequently stim-
ulated for 24 hours with 1 × 10
−4 or 1 × 10
−6 MS P .T h e
culture cells were rinsed with Phosphate buﬀered saline
(PBS) once and subsequently incubated with collagenase for
20 minutes in 37◦C. The cells were harvested and washed
with PBS twice. Subsequently, the harvested cells were
incubated with FITC-conjugated monoclonal antihuman
CD62P (BD Pharmingen) and PE-conjugated monoclonal
antihuman CD54 (BD Pharmingen) as well as isotype
control monoclonal antibodies (BD Pharmingen) in PBS
supplemented with 1% bovine serum albumin and 0.02%
NaN3. After being washed, the cells were ﬁxed with 2%
formaldehyde containing PBS. The ﬁxed cells were analyzed
by FACScan using the CellQuest software program (Becton
Dickinson). Data mining was performed using the FLOWJO
software program (Tree Star, Inc., Ashland, USA).
2.6. Measurement of the Concentration of Endogenous Nitrite.
The HMVECs were grown on 24-well plates (5 × 105
cells/well) and preincubated with 100μM pyliramine or
100ng/mL bepotastine besilate for 30 minutes and sub-
sequently stimulated for 24 hours with 1 × 10
−6 MS P .
Following stimulation, the supernatants were harvested.
The harvested samples were 10000MW ﬁltered and 5-fold
diluted prior to a Total NO/Nitrite/Nitrate Assay (R&D Sys-
tem). The measurement of the concentration of endogenous
nitrite wasperformedaccordingtotheprotocols providedby
the manufacturer. The results were obtained from the optical
density of each sample using a Model 680 Microplate Reader
(BIO-RAD) set at 540nm.
2.7. Statistical Analysis. The Prism5 software program
(Graph Pad Software, Calif, USA) was used for the statistic
analysis. The evaluating of the statistical values was per-
formed by the unpaired t-test. A P<. 05 was considered
signiﬁcant.
3. Results
To investigate the eﬀect of antihistamines on the SP-induced
basophil degranulation, the concentration of released β-
hexosaminidase was measured (Figure 1). As expected,Journal of Allergy 3
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Figure 1: Results of the β-hexosaminidase release assay. Control;
mock treated. SP: substance P. Error bar: standard deviation (SD).
N = 3–5.
1 ×10
−4 M of SP-induced the release of β-hexosaminidase,
while 1 × 10
−6 M of SP failed to induce the release. Inter-
estingly, bepotastine besilate signiﬁcantly suppressed the SP-
mediated release of β-hexosaminidase (P = .0009, unpaired
t-test, 1 × 10
−4 Mo fS Pv e r s u s1× 10
−4 M of SP + bepotas-
tine),whilepyliraminefailedtosuppress.Thisresultsuggests
that bepotastine besilate potentially aﬀects substance P
signaling.
Next, to verify the response of the HMVECs against
SP, the HMVECs were treated with 1 × 10
−6 and 1 ×
10
−4 M of SP or vehicle for 24 hours, and the medium
concentration of sICAM1 and sVCAM1 were measured
(Figure 2(a)). Unexpectedly, no signiﬁcant diﬀerences were
observed between the SP-treated and untreated groups. To
verify the localization and expression level of ICAM1 and
P-selectin in the HMVECs, immunochemical staining was
performed (Figure 2(b)). However, there are no signiﬁcant
changes between the SP-treated and untreated groups. Inter-
estingly, when the HMVECs were treated with bepotastine
besilate alone, the cell surface expression level of ICAM-1
or P-selectin had a tendency to decrease (Figure 2(b)). To
verify the above results, an FACS analysis for ICAM-1 and P-
selectinwasperformed(Figure3).Thecellsurfaceexpression
level of ICAM-1 and P-selectin slightly, but signiﬁcantly,
increased on the SP-treated HMVECs. Although, both
bepotastine besilate and pyliramine did not aﬀect the SP-
inducedupregulationofICAM-1andP-selectin,asigniﬁcant
decrease of the expression level of these adhesion molecules
on the HMVECs treated with bepotastine besilate alone was
reproduced by this assay.
Next, the concentration of synthesized nitrite in the
culture medium derived from the SP-treated HMVECs, with
orwithoutantihistamine,wasmeasured.TheSP(1×10
−6 M)
treated HMVECs derived from the conditioned medium
contained a signiﬁcantly high amount of nitrite in compari-
son to the control and vehicle treated medium. Interestingly,
the SP-induced synthesis of nitrite was signiﬁcantly inhibited
by bepotastine besilate, while that was not inhibited by
pyliramine-treatment. This data suggests that bepotasitine
besilate potentially inhibits the SP-induced NO synthesis of
endothelial cells (Figure 4).
4. Discussion
This report may identify a novel functional aspect of the
second generation antihistamines against the eﬀect of SP on
basophilsandendothelialcells.Ithasbeendemonstratedthat
mast cells populated in the chronic allergic skin diseases such
as atopic dermatitis, and prurigo nodularis [5]. Although,
histamine, which is released from the mast cell, is essential
for maintaining homeostasis in living organisms [16, 17],
an excessive response to histamine has been shown to play
an important role in the pathogenesis of chronic allergic
diseases, including atopic dermatitis [5]. From these facts,
the inhibition of excessive mast cell degranulation might be
a promising treatment of allergic skin diseases.
The mast cells of the human skin, but not those of
other tissues, are sensitive to stimulation by substance
P, compound 48/80, and other basic nonimmunological
stimuli [18]. The mechanism of mediator secretion induced
by these agents is distinct from that induced by IgE-
dependent stimulation [18]. As shown in Figure 1,b e p o t a s -
tine besilate, but not pyliramine, inhibited the SP-induced
degranulation of RBL-2H3. From this result, it is supposed
that bepotastine besilate might have an inhibitory action on
thedistinctpathwayofSP-induceddegranulationbesidesthe
H1-antagonistic action. Moreover, the FACS analysis caused
the unexpected result of a downregulation of the adhesion
molecules on the bepotastine besilate-treated HMVECs
(Figure 3). These advantages of bepotastine besilate will
provide good beneﬁts for the treatment of various kinds
of allergic skin diseases. However, there are strong doubts
about whether bepotastine besilate acts directly on SP-
mediated signaling or not, because bepotastine besilate has
failed to inhibit the SP-induced upregulation of the adhesion
molecules on the HMVECs (Figures 2 and 3). Although, it
is easy to assume that the eﬀect of bepotastine besilate might
dependonthecelltype,furtherexaminationsarestillneeded
to resolve this question.
This report also showed the remarkable results of the
eﬀect of bepotastine besilate on nitrite synthesis from the
SP-treated HMVECs. NO is a gaseous lipophilic free radical
cellular messenger that has pleiotropic actions including
regulation of blood pressure and vascular tone, inhibition of
platelet aggregation and leukocyte adhesion, and prevention
smooth muscle cell proliferation. NO is also known to
contribute to the formulation of various kinds of skin
diseases, such as urticaria [19], atopic dermatitis (AD)
[20], psoriasis [21], pemphigus [20], and systemic lupus
erythematosis [22]. Above all, it is striking that the serum
nitrate levels of the patients with AD signiﬁcantly increased
in comparison to the nonatopic controls and were also4 Journal of Allergy
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Figure 2: Eﬀects of SP on the expression level of adhesion molecules on HMVEC. (a) The concentration of sICAM1 and sVCAM1 in the
conditioned medium derived from SP-treated HMVEC. N = 3. Error bar: SD. (b) Immunolabeling of ICAM1 and P-selectin on HMVEC
with various treatments. Magniﬁcation, ×200.
correlated with the disease severity [20]. Because, there
are no reports describing any correlation between AD and
decreased blood pressure and no experience of examining
AD patients who suﬀer from decreased blood pressure in
our daily clinical practice, it is therefore assumed that an
increased serum concentration of NO in the AD patients
does not aﬀect the patient’s physiological condition. It does,
however, contribute to the exacerbation of skin eruptions.
In this study, bepotastine besilate was found to signiﬁcantly
inhibit the SP-induced nitrite synthesis in the HMVECs,Journal of Allergy 5
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Figure 3: Cell surface expression level of ICAM1 and P-selectin on HMVEC with various treatments. (a) Representative data of an FACS
analysis for ICAM1. The X axis indicates the ﬂuorescence intensity. The Y axis represents the cell count number. The heading includes the
data of mean ﬂuorescence. (b) The graph shows the mean ﬂuorescence intensity of immunolabeled ICAM1. Mean FL: mean ﬂuorescence.
Error bar: SD. N = 3. (c) Representative data of an FACS analysis for P-selectin. The X axis indicates the ﬂuorescence intensity. The Y axis
represents the cell count number. The heading includes the data of mean ﬂuorescence. (d) The graph shows the mean ﬂuorescence intensity
of immunolabeled P-selectin. Mean FL: mean ﬂuorescence. Error bar: SD. N = 3.6 Journal of Allergy
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Figure 4: The concentration of nitrite in conditioned medium
derived from HMVEC cultured with substance P and antihis-
tamines. Error bars: SD. N = 5–6.
while pyliramine failed to inhibit it (Figure 4). It should
therefore be considered that no side eﬀects of hypotension
have, thus far, been reported in patients treated with
bepotastine besilate, thus suggesting it to be potentially
usefulasasafeandpromisingantihistamineforpatientswith
NO-related skin diseases.
In fact, the above-mentioned possible clinical eﬀects of
bepotastine besilate are still hypothetical. It is therefore of
the utmost importance that more clinical data be generated
regarding these parameters in bepotastine besilate-treated
patients.
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